The first subject has been enrolled in Boston Scientific’s PLATINUM China trial, a head-to-head study comparing the safety and efficacy of the company’s Promus Element everolimus-eluting chromium coronary stent with the Taxus Liberte paclitaxel-eluting stent in treating patients with a single de novo atherosclerotic lesion. The prospective, randomized trial will enroll 500 subjects at 15 sites in China, the company says.